Shanghai clinical cohort for Parkinson's disease and multiple system atrophy (Reserve)
Official title: Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
Run by Ruijin Hospital · NCT07353463 · Data updated 2026-11-12
This project will try to use clinical exams, brain scans, electrical tests, genetic and biosample data from people with Parkinson's disease or multiple system atrophy to find early markers and better subtypes.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT07353463 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a clinical diagnosis of Parkinson's disease (per Chinese 2016 criteria) or clinically probable multiple system atrophy (per Chinese 2022 criteria) who are willing to provide informed consent, biospecimens, and undergo neuroimaging and clinical assessments are ideal candidates.
✕Probably not a fit
People who are unwilling or unable to provide biosamples, undergo imaging or follow-up visits, or who do not meet the clinical diagnostic criteria for PD or MSA are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a longitudinal observational cohort enrolling people with clinical Parkinson's disease and clinically probable multiple system atrophy in Shanghai. Participants will undergo standardized clinical assessments, multimodal imaging (MRI, PET/SPECT), electrophysiology, and biospecimen collection (blood, saliva, optional CSF) with long-term follow-up. Researchers will collect genetic data and compare 600 PD patients to 100 MSA patients to identify biomarkers, define precise subtypes, and model disease progression and treatment response. The assembled dataset is intended as a resource for translational research and development of novel therapies.
Why it matters
Potential benefit: If successful, the cohort could enable earlier diagnosis, more precise subtyping, and better prediction of disease course to guide personalized care.
How similar studies have gone: Multimodal cohort efforts such as PPMI and other longitudinal PD cohorts have found promising biomarker signals and subtype patterns, but translation to routine clinical care remains limited and further validation is needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
* Inclusion Criteria for Clinical PD Group: 1. Patients with a clinical diagnosis of Parkinson's disease (PD) according to the \_Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)\_. 2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments. 3. Provision of written informed consent * Inclusion Criteria for Clinical MSA Group: 1. Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022). 2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments. 3. Provision of written informed consent. * Exclusion Criteria for All Participants: 1. Patients with an unclear or uncertain diagnosis. 2. History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery. 3. Evidence of intracranial organic lesions on CT/MRI. 4. Severe anxiety, depression, or schizophrenia. 5. Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system. 6. Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments. 7. Anticipated poor compliance.
Where it's running
-
Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jun Liu, Professor
- Email: lj11128@rjh.com.cn
- Phone: +86-021-64370045
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Automated language analysis to help diagnose neurodegenerative diseases
A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.
-
Brain alpha-synuclein PET imaging in Parkinson's patients and healthy seniors
This open-label study tests a radioactive tracer called [18F]MK-0947 to see how it behaves in the brains of people with Parkinson's disease compared with healthy elderly volunteers.
-
Parkinson’s self-sufficiency and rehabilitation in a Czech spa setting
This intervention tests whether a Czech self-sufficiency test can be used with people with Parkinson’s disease and sees how spa-based rehabilitation affects independence, cognition, balance, and walking.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
Imaging PD progression with [18F]AV-133 using high- and standard-resolution PET
This study tests how [18F]AV-133 PET imaging changes over 12 months in people with Parkinson's disease and a small group of healthy controls.
-
Microelectrode-based brain stimulation for Parkinson’s and essential tremor
This early feasibility test checks a new microelectrode-based brain stimulation method in adults with Parkinson’s disease or essential tremor who are already getting deep brain stimulation implants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.